dual antiplatelet therapy

Post DES Dual Antiplatelet Therapy Still under Debate

The NIPPON trial (Nobori Dual Antiplatelet Therapy as Appropriate Duration) was a randomized study comparing a short&nbsp;dual antiplatelet therapy scheme (6 months) vs. a prolonged scheme (18 months) in patients receiving the Nobori drug eluting stent (Terumo, Tokyo, Japan) with a biodegradable abluminal polymer. It included 3,773 patients with chronic stable angina or acute coronary<a href="https://solaci.org/en/2017/07/18/post-des-dual-antiplatelet-therapy-still-under-debate/" title="Read more" >...</a>

Post DES Dual Antiplatelet Therapy Still under Debate

TOPIC: Benefits of Switching Dual Antiplatelet Therapy in Patients with ACS

Newer P2Y12 blockers are the front-line treatment and dual antiplatelet therapy is indicated for 1&nbsp;year after acute coronary syndrome (ACS). Both prasugrel and ticagrelor offer more ischemic benefit than clopidogrel during the initial phase; however, bleeding complications could increase in the long term. The objective of this study was to assess the safety and efficacy<a href="https://solaci.org/en/2017/05/23/benefits-of-switching-dual-antiplatelet-therapy-in-patients-with-acs/" title="Read more" >...</a>

doble antiagregacion plaquetaria sexo

Dual Antiplatelet Therapy in Men and Women: Are There Differences?

Courtesy of Dr. Agustín Vecchia. &nbsp; Currently, the duration of dual antiplatelet therapy (DAPT) after stent placement is one of the most highly debated topics in Cardiology. On the one hand, women are usually underrepresented in trials in our specialty; on the other, the fact that symptoms of coronary disease are different in women is well-known. &nbsp; The aim<a href="https://solaci.org/en/2016/09/12/dual-antiplatelet-therapy-in-men-and-women-are-there-differences/" title="Read more" >...</a>

Dual Antiplatelet Therapy after Everolimus Eluting Stenting

Original Title: Benefits and Risks of Extended Dual Antiplatelet Therapy after Everolimus-Eluting Stents. For the Dual Antiplatelet Therapy (DAPT) Study Investigators. Reference: James B. Hermiller et al. JACC: Cardiovascular Interventions 2015, online before print. The DAPT study had shown that continued aspirin plus thienopyridine beyond a year reduces ischemic events. Given the fairly low rate of thrombosis<a href="https://solaci.org/en/2015/12/11/dual-antiplatelet-therapy-after-everolimus-eluting-stenting/" title="Read more" >...</a>

OPTIMIZE: 3 versus 12 months dual antiplatelet therapy after angioplasty with DES

Currently the recommendation is 12 months of dual antiplatelet after a drug-eluting stent angioplasty. This study compared the 3 &#8211; months versus 12 months of dual antiplatelet&nbsp; after angioplasty with zotarolimus-eluting stent in real-world patients. This was a prospective, multicenter study randomized 1563 patients to receive aspirin and clopidogrel for 3 months and 1556 to<a href="https://solaci.org/en/2015/06/24/congress-item-6342/" title="Read more" >...</a>

Risks and benefits of extending dual antiplatelet therapy in patients with and without MI

Original title:&nbsp;Benefits and Risks of Extended Duration Dual Antiplatelet Therapy after PCI in Patients With and Without Acute Myocardial Infarction. The DAPT Study.&nbsp;Reference:&nbsp;Robert W. Yeh et al. J Am Coll Cardiol. 2015, online before print. The risks and benefits of prolonged antiplatelet therapy after PCI could be different in patients presenting with AMI compared to<a href="https://solaci.org/en/2015/04/21/n-5146/" title="Read more" >...</a>

Highlights TCT 2019

TCT 2019 | Onyx ONE: Durable Polymer vs. Polymer-Free Stent with Only One Month of Dual Antiplatelet Therapy

Courtesy of the SBHCI. This is the first randomized study comparing a durable-polymer drug-eluting stent (zotarolimus-eluting stent Onyx) and a polymer-free drug-eluting stent (biolimus-A9-coated stent BioFreedom), with only one month of dual antiplatelet therapy in patients at high risk for bleeding. Onyx ONE was a study conducted at 84&nbsp;sites that randomized 1:1 2000&nbsp;total patients at<a href="https://solaci.org/en/2019/09/30/tct-2019-onyx-one-a-randomized-trial-of-a-durable-polymer-drug-eluting-stent-vs-a-polymer-free-drug-coated-stent-in-patients-at-high-risk-of-bleeding-treated-with-1-month-dapt/" title="Read more" >...</a>

Doble antiagregación: menos es más en añosos.

Cardiovascular Risk, Dual Antiplatelet Therapy, and Age. What Should We Know?

Non-adherence to dual antiplatelet therapy varies with age and patients older than 75 years old are those who discontinue treatment most frequently. However, this characteristic in elderly patients was not associated with more cardiovascular events. Treatment compliance protected patients younger than 75 years old from events, while there was increased cardiovascular risk among this population<a href="https://solaci.org/en/2019/06/12/cardiovascular-risk-dual-antiplatelet-therapy-and-age-what-should-we-know/" title="Read more" >...</a>

Early Strut Coverage and Its Implications for Dual Antiplatelet Therapy

Optical coherence tomography (OCT)-guided drug-eluting stent implantation improves early strut coverage compared with angiography-guided angioplasty. No difference was observed in terms of strut coverage between permanent-polymer everolimus-eluting stents and bioresorbable-polymer biolimus-eluting stents. Short-term dual antiplatelet therapy may be feasible in selected patients with early strut coverage. &nbsp; This study sought to measure early strut coverage<a href="https://solaci.org/en/2018/12/14/early-strut-coverage-and-its-implications-for-dual-antiplatelet-therapy/" title="Read more" >...</a>

Seguridad de combinar los nuevos anticoagulantes y la doble antiagregación

Safety of Combining New Anticoagulant Agents and Dual Antiplatelet Therapy

Atrial fibrillation is the most common arrhythmia and its combination with a history of acute myocardial infarction or coronary angioplasty is quite frequent. According to this study (recently published in JACC), in a real-world population, the combination of direct anticoagulant agents and dual antiplatelet therapy reduces significantly the risk of bleeding and provides similar thromboembolic<a href="https://solaci.org/en/2018/11/20/safety-of-combining-new-anticoagulant-agents-and-dual-antiplatelet-therapy/" title="Read more" >...</a>

Top